Clinical Trial Update: A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating omacetaxine, azacitidine, and G-CSF for myelodysplastic syndromes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• G-CSF (filgrastim) (filgrastim)
• Omacetaxine (omacetaxine mepesuccinate)

Snippet

Sponsor: University of Florida | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: WITHDRAWN